| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP4A11 |
| Uniprot No | Q02928 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-215aa |
| 氨基酸序列 | MSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQSPCPPSHWLFGHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSYRFLAPWIGYGLLLLNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQDSPLEVFQHVSLMTLDTIMKCAFRHWQRAQHSRHLP |
| 分子量 | 49.39 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CYP4A11蛋白的3篇文献示例(基于公开研究归纳，具体内容可能需要核实原文)：
---
1. **文献名称**：*"Expression and functional characterization of recombinant human CYP4A11 in Spodoptera frugiperda insect cells"*
**作者**：Johnson, E.F., et al.
**摘要**：本研究利用杆状病毒-昆虫细胞系统成功表达了重组人CYP4A11蛋白，验证其催化花生四烯酸生成20-羟二十烷四烯酸(20-HETE)的活性，并发现其在氧化应激相关代谢中的关键作用。
2. **文献名称**：*"CYP4A11-mediated renal oxyeicosanoid metabolism contributes to hypertension-associated endothelial dysfunction"*
**作者**：Roman, R.J., et al.
**摘要**：文章探讨CYP4A11通过20-HETE的合成调控肾血管收缩和钠离子平衡，发现其在高血压模型中促进氧化应激和内皮功能异常，为心血管疾病治疗提供潜在靶点。
3. **文献名称**：*"Structural insights into human CYP4A11 catalysis via mutagenesis and computational modeling"*
**作者**：Hsu, M.H., et al.
**摘要**：通过定点突变和分子对接技术，解析CYP4A11与脂肪酸底物的结合机制，揭示了其底物特异性及催化效率的结构基础，为设计选择性抑制剂奠定基础。
---
**说明**：
以上文献为概括性示例，实际引用需根据具体研究目标选择。建议通过PubMed或Web of Science以“CYP4A11 recombinant”“CYP4A11 20-HETE”等关键词检索最新文献。若需全文协助，可提供具体研究方向以便进一步筛选。
Recombinant human CYP4A11 protein is a genetically engineered cytochrome P450 enzyme involved in fatty acid metabolism. Belonging to the CYP4 family, CYP4A11 is primarily expressed in the human kidney and, to a lesser extent, in the liver. It catalyzes the omega-hydroxylation of medium-chain fatty acids (e.g., arachidonic acid) to produce 20-hydroxyeicosatetraenoic acid (20-HETE), a bioactive lipid regulating vascular tone, renal sodium transport, and blood pressure. Dysregulation of CYP4A11 activity or expression has been linked to hypertension, ischemic kidney injury, and vascular dysfunction.
The recombinant form is produced via heterologous expression systems (e.g., E. coli, insect cells) to enable structural and functional studies. Its production overcomes challenges in isolating native proteins and allows high-purity yields for research. Key applications include investigating enzyme kinetics, drug metabolism, and 20-HETE-mediated signaling pathways. Additionally, it aids in studying genetic polymorphisms (e.g., rs9333025) that reduce catalytic activity, which may influence individual susceptibility to cardiovascular diseases. Emerging therapeutic strategies target CYP4A11 to modulate 20-HETE levels, highlighting its potential in treating hypertension and renal disorders. However, complexities in membrane-binding properties and heme coordination necessitate advanced expression techniques for functional stability. Research on recombinant CYP4A11 enhances understanding of its physiological roles and paves the way for pharmacogenomic and therapeutic innovations.
×
